Ignite Creation Date:
2025-12-24 @ 3:54 PM
Ignite Modification Date:
2026-02-21 @ 9:24 PM
Study NCT ID:
NCT02556892
Status:
COMPLETED
Last Update Posted:
2019-08-14
First Post:
2015-06-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor:
Janssen Pharmaceutical K.K.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-07-03
Start Date Type:
ACTUAL
Primary Completion Date:
2018-08-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-08-20
Completion Date Type:
ACTUAL
First Submit Date:
2015-06-30
First Submit QC Date:
None
Study First Post Date:
2015-09-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-08-12
Last Update Post Date:
2019-08-14
Last Update Post Date Type:
ACTUAL